Literature DB >> 22105215

Multiple sclerosis: Teriflunomide shows promise for MS treatment in phase III trial.

Heather Wood.   

Abstract

Entities:  

Year:  2011        PMID： 22105215     DOI： 10.1038/nrneurol.2011.184

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  2 in total

1.  A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

Authors:  P W O'Connor; D Li; M S Freedman; A Bar-Or; G P A Rice; C Confavreux; D W Paty; J A Stewart; R Scheyer
Journal:  Neurology       Date:  2006-03-28       Impact factor: 9.910

2.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Authors:  Paul O'Connor; Jerry S Wolinsky; Christian Confavreux; Giancarlo Comi; Ludwig Kappos; Tomas P Olsson; Hadj Benzerdjeb; Philippe Truffinet; Lin Wang; Aaron Miller; Mark S Freedman
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.